CCL2 and diabetic kidney disease: To determine the effects of VEPTP inhibition with mAb 109.1 on kidney endothelial activation, fibrosis, inflammation, and injury in DKD, we determined the mRNA expression of endothelial activation markers Angpt2, Edn1, Icam1 and Igfbp7, fibrosis markers Fn1, Ctgf, Acta2 and Col1a1, inflammatory markers Ccl2, Lcn2, and kidney injury marker (Havcr1) transcripts in the kidneys of DKD mice (db/db Unx ReninAAV) treated with the VEPTP blocking antibody or lisinopril.